RT Journal Article
SR Electronic
T1 Vaccine effectiveness of the BNT162b2 mRNA COVID-19 vaccine against RT-PCR confirmed SARS-CoV-2 infections, hospitalisations and mortality in prioritised risk groups
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.27.21257583
DO 10.1101/2021.05.27.21257583
A1 Hanne-Dorthe Emborg
A1 Palle Valentiner-Branth
A1 Astrid Blicher Schelde
A1 Katrine Finderup Nielsen
A1 Mie Agermose Gram
A1 Ida Rask Moustsen-Helms
A1 Manon Chaine
A1 Ulla Holten Seidelin
A1 Jens Nielsen
YR 2021
UL http://medrxiv.org/content/early/2021/06/02/2021.05.27.21257583.abstract
AB Objective To estimate in a real life setting, the vaccine effectiveness of the BNT162b2 mRNA vaccine against confirmed SARS-CoV-2 infection, hospital admission, and death among five priority groups for vaccinationDesign Cohort studySetting Roll-out of the BNT162b2 mRNA vaccine in DenmarkParticipants 864,096 individuals who were first inline to receive the BNT162b2 mRNA vaccine: 46,101 long-term care facility (LTCF) residents, 61,805 individuals 65 years and older living at home but requiring practical help and personal care (65PHC), 98,533 individuals ≥85 years of age (+85), 425,799 health-care workers (HCWs), and 231,858 individuals with comorbidities that predispose for severe COVID-19 disease (SCD).Intervention vaccination with BNT162b2 mRNA vaccineMain outcome measures RT-PCR confirmed SARS-CoV-2 infections, COVID-19 related admissions within 14 days after a confirmed SARS-CoV-2 infection, all-cause admission, COVID-19 related death within 30 days after confirmed SARS-CoV-2 infection, and all-cause death.Results Beyond 7 days after the second dose, the VE against SARS-CoV-2 infection in all groups ranged from 53-86%. In 65PHC, HCW and SCD, we observed a substantial reduction in risk of infection 0-7 days after the second dose ranging from 46-71%. The VE against COVID-19 related admissions ranged from 75-87% in all groups except +85 and HCWs where no events occurred. For COVID-19 related deaths, a significant VE was observed in LTCF residents (VE of 89%) and 65PHC (VE of 97%), whereas no events were observed in the three remaining groups. VE against all-cause death ranged from 26-73% in all groups except HCW where an insignificant VE was estimated. For all-cause admission, the VE ranged from 37-50% in all groups except in SCD where a negative VE was observed.Conclusion In a real-life setting and more than 7 days after the second dose of BNT162b2 mRNA was administered to the most vulnerable individuals, the vaccine was associated with a reduction of SARS-CoV-2 infection (53-86%) and COVID-19 related admissions (≥75%) or deaths (≥89%).Competing Interest StatementThe authors have declared no competing interest.Funding StatementNeither Statens Serum Institut nor any authors received funding for this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data included in this report is part of the Danish national COVID-19 surveillance system database at Statens Serum Institut. The data becomes or are already available for research upon reasonable request and with permission from the Danish Data Protection Agency and Danish Health and Medicines Authority. Ethics: We used only administrative register data for the study. According to Danish law, ethics approval is exempt for such research, and the Danish Data Protection Agency, which is a dedicated ethics and legal oversight body, thus waives ethical approval for our study of administrative register data, when no individual contact of participants is neccessary and only aggregate results are included as findings. The study is therefore fully compliant with all legal and ethical requirements and there are no further processes available regarding such studies.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe individual level data used in this study are sensitive and cannot be publicly shared. Any data requests should be sent to Forskerservice at the Danish Health and Medicin Authority. Aggregated surveillance data can are freely available online: https://covid19.ssi.dk/